YoungCAMillsRRogD, et al. Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy. J Neurol Sci2021; 426: 117437.
2.
RoccaMAValsasinaPColomboB, et al. Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. Eur J Neurol2021; 28(7): 2249–2258.
3.
NourbakhshBRevirajanNMorrisB, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: A randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol2021; 20(1): 38–48.
4.
BradleyL. Delayed amantadine toxicity causing apparent progression of multiple sclerosis. Mult Scler2021. Epub ahead of print. DOI: 10.1177/13524585211035737.
